<DOC>
	<DOCNO>NCT03024489</DOCNO>
	<brief_summary>Cyclin D kinase 4 ( CDK4 ) key regulator G1-S transition cell cycle . Alterations CDK4-cyclin D-retinoblastoma ( Rb ) pathway may lead carcinogenesis many cancer . Several mechanism describe : ( ) Amplification overexpression cyclin D1 , ( ii ) Amplification CDK4 , ( iii ) Activating mutation CDK4 , ( iv ) Loss CDK4 inhibitor , p16 ( CDKN2A ) . Human Papilloma Virus ( HPV ) play major role squamous cell carcinoma head neck ( SCCHN ) carcinogenesis . It induce many alteration CDK4-Cyclin D-Rb apoptotic pathway up-regulation p16 , loss Rb p53 function . A novel therapy HPV-negative SCCHN clearly unmet medical need . Palbococlib ( PD 0332991 ) orally active , highly selective inhibitor CDK4/6 ability block Rb phosphorylation low nanomolar range . The advanced development treatment metastatic breast cancer . In addition , palbociclib show radiosensitization property . Since combination cetuximab radiation improve PFS overall survival ( OS ) locally advance unresectable SCCHN compare radiation alone , provide strong rationale evaluate combination palbociclib , cetuximab , radiation locally advance unresectable SCCHN . Because many genetic alteration SCCHN significantly involve CDK4-cyclin D-Rb pathway , predictive biomarker ( ) palbociclib combination explore . Thus , investogators propose non-randomized , dose escalation , phase I study design determine maximum tolerate dose ( MTD ) toxicity palbociclib , cetuximab , IMRT locally advance unresectable SCCHN .</brief_summary>
	<brief_title>Palbociclib With Cetuximab IMRT Locally Advanced Squamous Cell Carcinoma</brief_title>
	<detailed_description>The enrollment initial patient cohort 3 6 patient follow traditional `` 3 + 3 '' dose escalation scheme ( see table ) . The patient treat palbociclib , cetuximab , IMRT start Dose Level ( DL ) 1 . Subsequent patient cohort ( ) enrol depend safety tolerability initial cohort . If &lt; 33 % patient treat Dose Level 1 experience DLT ( see definition ) end treatment ( 56 day ) , next cohort 3 patient enrol treated Dose Level 2 . If 2 treatment-related DLTs observe Dose Level 1 , patient accrue Dose Level -1 . The MTD define maximum dose level ≤1/6 patient DLTs . At MTD RP2D , accrue 15 locally advanced unresectable p16-negative SCCHN patient allow definitive evaluation tolerability , correlative endpoint preliminary efficacy . CT/PET scan perform 3 month last dose radiation evaluate residual disease . Patients residual disease consider salvage surgery follow standard care . - IMRT administer 5 day on/2 day total dose 70 Gy 33 fraction . - Cetuximab administer 400 mg/m2 IV 7 day ( day -7 ) start radiation 250 mg/m2 IV weekly 7 week . - Palbociclib administer orally daily 3 week-on 1-week IMRT ( Day 1-21 Day 29-49 ) .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Locally advanced histology cytology proven squamous cell carcinoma oral cavity , oropharynx , larynx , hypopharynx . 2 . Primary tumor locoregional lymph node must consider unresectable . 3 . Age ≥ 18 yea old . 4 . Available tissue determine HPV status biomarkers interest . 5 . ECOG status ≤ 1 . 6 . Adequate bone marrow , liver , renal function , define : Platelet count ≥150 x 109/L , Absolute Neutrophile Count ( ANC ) ≥1.5 x 109/L , Hgb ≥9 gm/dL ALT AST ≤ 1.5 upper limit normal ( ULN ) ; serum total bilirubin ≤ ULN Serum creatinine ≤ 1.5 x ULN , calculate measure creatinine clearance ( CockcroftGault Equation ) ≥ 50 mL/min Magnesium ≥ low limit normal 7 . Women childbearing potential must negative pregnancy test perform within 7 day prior start study drug . 8 . Male female subject childbearing potential must agree use doublebarrier contraceptive measure , oral contraception , avoidance intercourse study 6 month last investigational drug dose receive . 9 . Subject legal representative must understand investigational nature study sign Independent Ethics Committee/Institutional Review Board approve write informed consent form prior receive study related procedure . Potential subject meet ANY follow exclusion criterion eligible enrollment study : 1 . SCCHN patient distance metastasis . 2 . Major surgery &lt; 4 week minor surgery &lt; 2 week prior first day study treatment . 3 . Patients previous chemotherapy cancer treatment radiation head neck area . 4 . Patients previously treat CDK4/6 inhibitor cetuximab . 5 . Active cardiac disease describe : Left ventricular ejection fraction ( LVEF ) &lt; 50 % Multiple Grated acquisition ( MUGA ) scan echocardiogram ( ECHO ) . QTc &gt; 480 msec screen EKG ( use QTcF formula ) . Congenital long QT syndrome Myocardial infarction active uncontrolled angina pectoris within last 6 month prior first day study treatment Uncontrolled significant cardiac arrhythmia except benign premature ventricular contraction ( PVC ) premature atrial contraction ( PAC ) . Symptomatic pericarditis History cardiomyopathy 6 . Active clinically serious infection serious uncontrolled medical condition . 7 . Substance abuse , medical , psychological social condition may , opinion Investigator , interfere patient 's participation study evaluation study result . 8 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption palbociclib . 9 . Known HBV , HCV , and/or HIV infection . 10 . Patients currently treat drug know strong inhibitor inducer isoenzyme CYP3A , treatment discontinue switched different medication prior start study drug . 11 . Patients take herbal medication certain fruit within 7 day prior start study drug . Herbal medication include , limited St. John 's wort , Kava , ephedra ( huang ) , gingko biloba , dehydroepiandrosterone ( DHEA ) , yohimbe , saw palmetto , ginseng . Fruits include CYP3A inhibitor Seville orange , grapefruit , pummelo , exotic citrus fruit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Phase I/II</keyword>
</DOC>